Peritoneal dialysis solution comprising electrolytes in physiological amounts and at least one osmotically active substance which additionally comprises as antimicrobial substance sorbic acid in an amount of 0.001 to 1% by weight and a pH value of 4 to 7.

A liquid water base ibuprofen composition for oral administration is described, the ibuprofen being maintained in suspension by a combination of primary suspending agents and being taste masked by primary taste masking agents, the composition also containing a buffer acid to adjust the pH of the composition to between 1.5 and up to about 3.5 and to provide a buffer capacity within the range of 0.03 to 0.05 between the initial pH and a pH which is 1.0 pH unit higher than the initial pH.

Compositions and methods for the prevention of adhesion development involve the administration of therapeutic formulations of a halogenated organic compound to a patient in need of treatment. The formulations can include suitable carriers for optimal administration.

Use of a preparation comprising formic acid as an active ingredient for the manufacture of a medicament for the treatment of skin warts caused by a papilloma virus in a mammal by topical administration on the affected area.

Calcium salts, in particular calcium trifluoroacetate, are added to medicaments to provide cytotoxic and antitumoral activity. The medicaments can be administered to cancer patients as part of a method of treating a cancer patient. The medicaments can also be applied to a tumor to treat the tumor. The medicaments may be administered or applied orally or parenterally.

A pharmaceutical composition comprising as an active phosphorylation potential enhancing substance a pharmaceutically-acceptable salt of an alpha-keto carboxylic acid thereof alone or in combination with nicatinamide and creatine and, its use and products containing the same.

The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is ...

The present invention provides novel metastasis suppressory agents with a lowered degree of toxicity, comprising ursolic acid or its salt as an active ingredient, which can be administered to patients per os or through injection, thus enabling the patients to receive post-operative ambulatory treatment.

A method of treating a victim suffering from cerebral ischemia or treating a patient expected to suffer an ischemic insult comprises administering a therapeutically effective amount of a dichloroacetate. The post-treatment occurs within about 48 hours of the ischemic insult and lasts for up to about two days.

This invention provides a method of treating inflammation and arthritis employing certain prostanoic acid derivatives. Pharmaceutical formulations employing these derivatives are also provided.